Last reviewed · How we verify
USL255
USL255 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.
USL255 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | USL255 |
|---|---|
| Also known as | Topiramate extended-release |
| Sponsor | Upsher-Smith Laboratories |
| Drug class | sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting Nav1.5, USL255 is expected to reduce the risk of atrial fibrillation and subsequent stroke. This mechanism is thought to be beneficial for patients with atrial fibrillation who are at high risk of stroke.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Increased risk of atrial fibrillation
Key clinical trials
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- Pharmacokinetics and Pharmacodynamics of Topiramate for Weight Loss in Youth: PHARMATOP (EARLY_PHASE1)
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study (PHASE4)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (PHASE4)
- Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery (PHASE4)
- Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- USL255 CI brief — competitive landscape report
- USL255 updates RSS · CI watch RSS
- Upsher-Smith Laboratories portfolio CI